xr:d:DAFgdOhAKPA:6,j:3169841521,t:23042114

Multiple Myeloma Market, Size, Share, Growth ⅼ Forecast (2023 – 2030) ⅼ Renub Research

No comments

Multiple Myeloma Market shall be US$ 16.31 Billion by 2030, according to Renub Research. One of the primary factors is an aging population, as multiple myeloma is more prevalent among older individuals.

 

Renub Research has recently released a report titled “ Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis” providing a detailed industry analysis that includes market share insights. In addition, the report covers research on competitors and regions and current advancements in the multiple myeloma market. The Multiple Myeloma Industry shall experience a CAGR of nearly 6.04% from 2023 to 2028. The increasing prevalence of multiple myeloma is aiding the rise of the multiple myeloma market.

 

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/multiple-myeloma-market-p.php

 

American Society of Clinical Oncology (ASCO) projects that approximately 35,730 adults in the United States, comprising 19,860 men and 15,870 women, will receive a multiple myeloma diagnosis in 2023, with an estimated 12,590 deaths, including 7,000 men and 5,590 women, resulting from the disease in the same year. The aging population worldwide has also contributed to the development of this market. The United Nations Population Division’s new world population report estimates that the number of people aged 80 or over is projected to triple, from 157 million in 2022 to 459 million in 2050.

 

Moreover, the availability of advanced diagnostics tools and the development of novel therapies have improved the survival rate of multiple myeloma patients, leading to increased demand for these treatments. For instance, Takeda carried out Phase I/Phase II multicenter trials in December 2022 to examine the safety, efficacy, tolerability, and immunogenicity of Modakafusp Alfa in patients with relapsed or refractory multiple myeloma. Additionally, the increasing adoption of targeted therapies and the use of combination therapies have also contributed to the growth of the multiple myeloma market.

Furthermore, the rising investments in research and development activities by pharmaceutical companies and academic institutions have resulted in the development of more effective and efficient treatments for multiple myeloma. For example, in March 2022, Sanofi entered into a strategic collaboration with Blackstone on a risk-sharing basis. As per the collaboration, Blackstone Life Sciences would invest up to EUR 300 million (USD 320.51 million) to expedite the pivotal global studies and clinical development program for Sarclisa, an anti-CD38 antibody, for treating multiple myeloma patients via subcutaneous formulation and delivery. Lastly, the increasing awareness about multiple myeloma and the availability of treatment options among patients and healthcare professionals have also contributed to the growth of the multiple myeloma market.

 

Targeted Therapy dominance in the multiple myeloma market due to Selective Cancer Cell Targeting and Personalized Treatment Plans with practical outcomes

 

Other Post You May Be Interested In

The reason for the dominance of targeted therapy in the multiple myeloma market is its ability to selectively target cancer cells while sparing healthy cells, resulting in fewer side effects and better outcomes for patients. Additionally, targeted therapies can be customized to a patient’s specific cancer type and genetic profile, allowing personalized treatment plans.

 

Another factor contributing to the dominance of targeted therapy in the multiple myeloma market is its effectiveness in treating multiple myeloma, with many targeted therapies showing high response rates and improved survival rates in clinical trials. Finally, the approval of several new targeted therapies for multiple myeloma in recent years has expanded treatment options for patients, further contributing to the growth and dominance of this market segment.

 

Aging Population of Females is increasing the prevalence of Multiple Myeloma in Women, benefiting the multiple myeloma market

 

The growth of female patients in the multiple myeloma market can be due to increased awareness and early disease diagnosis among women, leading to better detection and treatment. Moreover, as the population ages, more women are developing multiple myeloma, and the risk of the disease increases with age. Furthermore, an increasing number of clinical trials are focusing on the study of multiple myeloma in female patients, which is helping to improve our knowledge of the disease and provide more efficient treatment alternatives for women.

 

 𝑭𝒐𝒓 𝑴𝒐𝒓𝒆 𝑫𝒆𝒕𝒂𝒊𝒍𝒔, 𝑮𝒓𝒂𝒃 𝒕𝒉𝒆 Free Sample Report: https://www.renub.com/request-sample-page.php?gturl=multiple-myeloma-market-p.php

France robust Healthcare System and Favorable Regulatory Environment contributed to its growing Epidemiology Share in the Multiple Myeloma Market

France robust healthcare system strongly emphasizes cancer screening and early detection, resulting in the identification and reporting of more multiple myeloma cases, which played a significant role in the growth of France’s epidemiology share in the multiple myeloma market. The country also has an intense research and development infrastructure for cancer treatments, which can lead to better treatment outcomes and longer survival rates for multiple myeloma patients attracting more patients to seek treatment in France, contributing to the country’s epidemiology share.

 

In addition, France has a favorable regulatory environment for clinical trials, which can attract pharmaceutical companies to conduct tests in the country leading to more innovative treatments becoming available in France, further contributing to the country’s epidemiology share.

 

United States (U.S.) has the Lion’s Share in the Multiple Myeloma Market

The U.S. has a large patient population with multiple myeloma, which makes it an attractive market for pharmaceutical companies to invest in and develop new treatments. According to the American Cancer Society, approximately 35,730 individuals shall receive a new diagnosis of multiple myeloma in the United States in 2023, with an estimated 12,590 deaths to occur as a result of the disease. Therefore, conducting clinical trials and studies on a larger patient population provides an opportunity for more comprehensive data and evidence on treatment effectiveness.

 

The U.S. has a favorable regulatory environment for clinical trials and drug approvals, encouraging pharmaceutical companies to conduct studies and bring products to market quickly. In addition, a stable economy provides a conducive environment for investments in research and development, making the U.S. an attractive market for stakeholders in the multiple myeloma market.

 

Market Summary:

 

  • Treatment Types– The Report covers the Multiple Myeloma Market by treatment types from 3 viewpoints (Targeted therapy, Chemotherapy, and Others).
  • Gender share– The Multiple Myeloma Market, by gender share, break up into 2 viewpoints (Male and Female).
  • Epidemiology Share–By Epidemiology share, the Multiple Myeloma Market is broken up into 10 viewpoints (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia).
  • Countries– By countries, the Multiple Myeloma Market breaks up into 10 viewpoints (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia).

 

Related Reports

Prostate Cancer Diagnostics Market, Size, Global Forecast 2023-2028

Cervical Cancer Screening Market, Size, Global Forecast 2023-2028

Non-Small Cell Lung Cancer (NSCLC) Market will reach US$ 25.71 Billion in 2027

Lung Cancer Screening Market, Size, Global Forecast 2022-2027

 

About the Company:

 

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Contact Us:

Renub Research         

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Web: www.renub.com

SHARE NOW
Tagged with

Leave a Reply

Your email address will not be published. Required fields are marked *